<p>Enzolytics Inc. 发布 2024 年年度报告</p>
<p>Enzolytics Inc. 已发布截至 2024 年 12 月 31 日的年度报告。公司报告的总流动资产为 200,005,177 美元，较去年减少了 360,014,682 美元。值得注意的是，Enzolytics 与 Sagaliam Acquisition Corp.签署了一项重要的业务合并协议，导致其运营子公司 Virogenetics, Inc.和 Biogenysis, Inc.以价值 4.5 亿美元的股票交易方式出售。随后，一项更新协议将 Biogenysis, Inc.的所有权归还给 Enzolytics，而 Virogenetics, Inc.则以 20,000,000 股 Sagaliam Acquisition Corp.的股票进行交换。完整报告可通过以下链接访问。</p>

ENZC

<p>Enzolytics Inc. 发布了其 2024 年度报告，显示总流动资产为 200,005,177 美元，较去年 360,014,682 美元有所下降。报告强调与 Sagaliam Acquisition Corp. 的重大业务合并，导致其子公司 Virogenetics, Inc. 和 Biogenysis, Inc. 以 4.5 亿美元的价格出售。随后，Biogenysis, Inc. 被归还给 Enzolytics，而 Virogenetics, Inc. 则以 2000 万股 Sagaliam Acquisition Corp. 进行交换</p>

<p>Enzolytics Inc. Releases 2024 Annual Report</p>
<div class="lb-trans"><p>Enzolytics Inc. 发布 2024 年年度报告</p>
</div><p>Enzolytics Inc. has released its annual report for the year ending December 31, 2024. The company reported total current assets of $200,005,177, a decrease from $360,014,682 in the previous year. Notably, Enzolytics executed a significant business combination agreement with Sagaliam Acquisition Corp., resulting in the sale of its operating subsidiaries, Virogenetics, Inc. and Biogenysis, Inc., in a stock transaction valued at $450 million. Subsequently, a novation agreement returned the ownership of Biogenysis, Inc. to Enzolytics, while Virogenetics, Inc. was exchanged for 20,000,000 shares of Sagaliam Acquisition Corp. The full report can be accessed through the link below.</p>
<div class="lb-trans"><p>Enzolytics Inc. 已发布截至 2024 年 12 月 31 日的年度报告。公司报告的总流动资产为 200,005,177 美元，较去年减少了 360,014,682 美元。值得注意的是，Enzolytics 与 Sagaliam Acquisition Corp.签署了一项重要的业务合并协议，导致其运营子公司 Virogenetics, Inc.和 Biogenysis, Inc.以价值 4.5 亿美元的股票交易方式出售。随后，一项更新协议将 Biogenysis, Inc.的所有权归还给 Enzolytics，而 Virogenetics, Inc.则以 20,000,000 股 Sagaliam Acquisition Corp.的股票进行交换。完整报告可通过以下链接访问。</p>
</div>